David Edmund Szymkowski

List of Publications by Year
in descending order

56	3,371	186265	149698
papers	citations	28 h-index	56 g-index

61	61	61	4216
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease. Journal of Neuroscience, 2006, 26, 9365-9375.	3.6	331
2	Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants. Science, 2003, 301, 1895-1898.	12.6	222
3	MUC17, a Novel Membrane-Tethered Mucin. Biochemical and Biophysical Research Communications, 2002, 291, 466-475.	2.1	187
4	Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain, 2011, 134, 2736-2754.	7.6	174
5	Cloning of the Amino-terminal and 5â€²-Flanking Region of the Human MUC5AC Mucin Gene and Transcriptional Up-regulation by Bacterial Exoproducts. Journal of Biological Chemistry, 1998, 273, 6812-6820.	3.4	160
6	Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection. Journal of Immunology, 2007, 179, 1872-1883.	0.8	148
7	Antibody-Mediated Coengagement of FcÎ³RIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus. Journal of Immunology, 2011, 186, 4223-4233.	0.8	142
8	Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcÎ³RIIb with Fc-engineered antibodies. Molecular Immunology, 2008, 45, 3926-3933.	2.2	128
9	Soluble TNF Mediates the Transition from Pulmonary Inflammation to Fibrosis. PLoS ONE, 2006, 1, e108.	2.5	116
10	Oligodendroglial TNFR2 Mediates Membrane TNF-Dependent Repair in Experimental Autoimmune Encephalomyelitis by Promoting Oligodendrocyte Differentiation and Remyelination. Journal of Neuroscience, 2016, 36, 5128-5143.	3.6	113
11	Phorbol 12-Myristate 13-Acetate Up-regulates the Transcription of MUC2Intestinal Mucin via Ras, ERK, and NF-ÎºB. Journal of Biological Chemistry, 2002, 277, 32624-32631.	3.4	93
12	Hippocampal TNFÎ± Signaling Contributes to Seizure Generation in an Infection-Induced Mouse Model of Limbic Epilepsy. ENeuro, 2017, 4, ENEURO.0105-17.2017.	1.9	88
13	Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-ÎºB. Brain, 2011, 134, 2722-2735.	7.6	85
14	Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcÎ³RIIb with Fc-engineered antibody. Journal of Allergy and Clinical Immunology, 2012, 129, 1102-1115.	2.9	81
15	Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia. Journal of Neuroinflammation, 2014, 11, 203.	7.2	79
16	Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia. JCI Insight, 2017, 2, .	5.0	72
17	Transmembrane TNFâ€Î± is sufficient for articular inflammation and hypernociception in a mouse model of gout. European Journal of Immunology, 2016, 46, 204-211.	2.9	67
18	Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood, 2010, 116, 575-583.	1.4	63

#	Article	IF	Citations
19	Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice. Journal of Neuroinflammation, 2014, 11, 159.	7.2	62
20	Harnessing Fc receptor biology in the design of therapeutic antibodies. Current Opinion in Immunology, 2016, 40, 78-87.	5.5	59
21	Soluble TNF, but not membrane TNF, is critical in LPS-induced hepatitis. Journal of Hepatology, 2010, 53, 1059-1068.	3.7	56
22	Neutralization of Membrane TNF, but Not Soluble TNF, Is Crucial for the Treatment of Experimental Colitis. Inflammatory Bowel Diseases, 2013, 19, 246-253.	1.9	56
23	Developing antisense oligonucleotides from the laboratory to clinical trials. Drug Discovery Today, 1996, 1, 415-428.	6.4	51
24	Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Antiâ€CD19 Antibody That Coengages B Cell Antigen Receptor Complex and FcÎ³ Receptor IIb Inhibitory Receptor. Arthritis and Rheumatology, 2014, 66, 1153-1164.	5.6	51
25	Dominantâ€Negative Tumor Necrosis Factor Protects fromMycobacterium bovisBacillus Calmetteâ€GuÃ©rin (BCG) and Endotoxinâ€Induced Liver Injury without Compromising Host Immunity to BCG andMycobacterium tuberculosis. Journal of Infectious Diseases, 2009, 199, 1053-1063.	4.0	48
26	Inhibition of Soluble Tumor Necrosis Factor Ameliorates Synaptic Alterations and Ca2+ Dysregulation in Aged Rats. PLoS ONE, 2012, 7, e38170.	2.5	47
27	Roles of Soluble and Membrane TNF and Related Ligands in Mycobacterial Infections: Effects of Selective and Non-selective TNF Inhibitors During Infection. Advances in Experimental Medicine and Biology, 2011, 691, 187-201.	1.6	29
28	An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells. Molecular and Cellular Biology, 1995, 15, 290-297.	2.3	28
29	Suppression of mast cell degranulation through a dual-targeting tandem IgEâ€“IgG Fc domain biologic engineered to bind with high affinity to FcÎ³RIIb. Immunology Letters, 2012, 143, 34-43.	2.5	28
30	Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcÎ³RIIb and CD19. MAbs, 2014, 6, 991-999.	5.2	28
31	Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus. Antiviral Research, 2000, 48, 187-196.	4.1	27
32	Immunotherapy with Long-Lived Anti-CD123 Ã— Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia. Blood, 2014, 124, 2316-2316.	1.4	27
33	Tuning T Cell Affinity Improves Efficacy and Safety of Anti-CD38 Ã— Anti-CD3 Bispecific Antibodies in Monkeys - a Potential Therapy for Multiple Myeloma. Blood, 2015, 126, 1798-1798.	1.4	26
34	Allergic Lung Inflammation Is Mediated by Soluble Tumor Necrosis Factor (TNF) and Attenuated by Dominant-Negative TNF Biologics. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 731-739.	2.9	25
35	Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis. Clinical and Experimental Immunology, 2012, 168, 165-177.	2.6	25
36	Topical Administration of a Soluble TNF Inhibitor Reduces Infarct Volume After Focal Cerebral Ischemia in Mice. Frontiers in Neuroscience, 2019, 13, 781.	2.8	25

#	Article	IF	Citations
37	Immune suppression in cynomolgus monkeys by XPro9523. MAbs, 2013, 5, 384-396.	5.2	23
38	Creating the next generation of protein therapeutics through rational drug design. Current Opinion in Drug Discovery & Development, 2005, 8, 590-600.	1.9	21
39	Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosisâ€“Directed Therapeutics. Journal of Immunology, 2014, 192, 4122-4133.	0.8	18
40	Identification and characterization of aDictyostelium discoideumribosomal protein gene. Nucleic Acids Research, 1990, 18, 4695-4701.	14.5	17
41	Electron Microscopy of DNA Excision Repair Patches Produced by Human Cell Extracts. Journal of Molecular Biology, 1993, 231, 251-260.	4.2	16
42	ADictyostelium discoideumcDNA coding for a protein with homology to the rat ribosomal protein L7. Nucleic Acids Research, 1989, 17, 5393-5393.	14.5	15
43	Immunotherapy with Long-Lived Anti-CD38 Ã— Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human Myeloma Cell Lines and CD38+ Cells in Monkeys: A Potential Therapy for Multiple Myeloma. Blood, 2014, 124, 4727-4727.	1.4	14
44	Immunotherapy with Long-Lived Anti-CD20 Ã— Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human B Cell Lines and of Circulating and Lymphoid B Cells in Monkeys: A Potential Therapy for B Cell Lymphomas and Leukemias. Blood, 2014, 124, 3111-3111.	1.4	12
45	Too many targets, not enough target validation. Drug Discovery Today, 2001, 6, 397.	6.4	11
46	Inhibition of TNF reduces mechanical orofacial hyperalgesia induced by Complete Freundâ€™s Adjuvant by a TRPV1-dependent mechanism in mice. Pharmacological Reports, 2017, 69, 1380-1385.	3.3	11
47	Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and FcÎ³ receptor IIb in non-autoimmune-prone and SLE-prone mice. Journal of Translational Autoimmunity, 2021, 4, 100075.	4.0	9
48	Trypanosoma brucei growth control by TNF in mammalian host is independent of the soluble form of the cytokine. Scientific Reports, 2017, 7, 6165.	3.3	8
49	Rational optimization of proteins as drugs: a new era of ?medicinal biology?. Drug Discovery Today, 2004, 9, 381-383.	6.4	6
50	Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via FcÎ³RIIb on Liver Sinusoidal Endothelial Cells by Endocytosis. Journal of Immunology, 2021, 206, 1284-1296.	0.8	6
51	Target validation joins the pharma fold. Targets, 2003, 2, 8-9.	0.3	4
52	Timely lessons for target-based discovery of anti-inflammatory drugs. Drug Discovery Today, 2005, 10, 14-17.	6.4	1
53	Suppression Of IgE Production By XmAb7195, An Fc-Engineered Antibody That Specifically Coengages Inhibitory Receptor Fc?RIIb With IgE-BCR. , 2011, , .		0
54	Central but not peripheral administration of XPro1595 is therapeutic following moderate spinal cord injury in mice. Journal of Neuroimmunology, 2014, 275, 114-115.	2.3	0

#	Article	IF	Citations
55	A1.84â€...Switching off B cells by Fc-engineered anti-CD19 antibody (XmAb5871). Annals of the Rheumatic Diseases, 2014, 73, A37.1-A37.	0.9	0
56	Hypersensitivity to Cisplatin in Mouse Leukemia L1210/0 Cells: An XPG DNA Repair Defect. , 1996, , 317-326.		0